1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Evelo’s Phase II Data Suggest Strong Position In Mild-To-Moderate Psoriasis

Analysts say biotech’s EDP1815 may offer similar efficacy to Amgen’s Otezla, with better safety. Evelo says data offer new proof for its small intestinal axis approach to inflammatory disease.

PSORIASIS Text, On Background of Medicaments Composition, Stethoscope, mix therapy drugs doctor flu antibiotic pharmacy medicine medical
Evelo candidate may offer relief for mild-to-moderate psoriais patients

Evelo Biosciences, Inc. unveiled Phase II data on 27 September indicating that its small intestinal axis-directed (SINTAX) therapeutic candidate EDP1815 can provide statistically significant clearance of psoriasis in mild-to-moderate cases with the safety profile of a placebo. The Cambridge, MA-based firm, a Flagship Pioneering portfolio company, says its SINTAX approach is differentiated from other microbiome therapies and may offer a new modality in immunology and other therapeutic areas.

The 249-patient study tested one-, four- and 10-capsule regimens of EDP1815 – an oral biologic that contains a single microbial strain optimized for pharmacological properties – against placebo in mild-to-moderate...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

GSK’s Nucala Set For Dupixent Face-Off After FDA COPD Nod

 
• By Kevin Grogan

The UK major's asthma drug gets a key expanded approval.

Merus Bispecific Impresses In Head And Neck Cancer

 
• By Andrew McConaghie

Updated Phase II results from petosemtamab have impressed ahead of ASCO, outshining Keytruda monotherapy and its bispecific rival from Bicara.

Boehringer’s CMO On How AI, Integrated Evidence Generation Underpin Its Ambitious Launch Plans

 
• By Alexandra Shimmings

The German company has big plans for the next five years or so. Scrip speaks to its chief medical officer Lykke Hinsch Gylvin about how it is using AI and other innovative approaches to make good on its ambitions.

Sanofi Makes Alzheimer’s Bet With Vigil Buy

 
• By Kevin Grogan

The French drugmaker is expanding its neurology activities with the $470m deal.

More from R&D

Sanofi Makes Alzheimer’s Bet With Vigil Buy

 
• By Kevin Grogan

The French drugmaker is expanding its neurology activities with the $470m deal.

New Vaccine Framework Avoided Worst-Case Scenario, Analysts Say

 
• By Joseph Haas

The new US FDA vaccine guidelines introduced on 20 May might cause financial woes for Moderna, but overall vaccine makers should not be as impacted as feared.

Merck KGaA Plans Phase III For Enpatoran After Mixed Phase II Lupus Data

 
• By Jessica Merrill

The Phase II study testing the novel TLR7/8 inhibitor met the primary endpoint in a cohort of patients with cutaneous lupus erythematosus and systemic lupus erythematosus with rash, but did not in patients with SLE.